Hosted on MSN21d
Regeneron projects EYLEA HD growth with new approvals and prefilled syringe launch in 2025
CEO Leonard Schleifer highlighted 10% revenue growth in Q4 2024, attributed to strong performance from Dupixent, Libtayo, and EYLEA HD. He emphasized the acceleration in EYLEA HD uptake expected ...
Fortune2y
Leonard Schleifer
Regeneron is a research-oriented biotech, founded by Schleifer, that had no product on the market for its first 20 years. Today its monoclonal antibodies, particularly Eylea for retinal diseases ...
Business Insider India5y
Pharma CEOs got into a heated debate over why people hate the industry
The panel featured Gilead CEO John Milligan, Pfizer CEO Ian Read, incoming Eli Lilly CEO David Ricks, Astellas Americas President Jim Robinson, and Regeneron CEO Leonard Schleifer. After some ...
Hosted on MSN7mon
Regeneron Pharmaceuticals' Q2 Earnings Exceed Estimates, Driven By Its Top-Selling Eczema And Eye Drugs
“Regeneron had a strong quarter, with total revenue up 12% driven by notable growth for EYLEA HD, Dupixent, and Libtayo,” said Leonard S. Schleifer, Board co-Chair, President and Chief ...
Fortune4y
Leonard Schleifer
The New York–based biotech Schleifer founded in 1988 has been much in the news this year for the drug, an antibody cocktail, it developed to fight COVID-19—and which was used in October to ...